Calcineurin/NFAT-dependent regulation of 230-kDa bullous pemphigoid antigen (BPAG1) gene expression in normal human epidermal keratinocytes. 2008

Takayuki Aizu, and Katsuto Tamai, and Hajime Nakano, and Daiki Rokunohe, and Yuka Toyomaki, and Jouni Uitto, and Daisuke Sawamura
Department of Dermatology, Hirosaki University School of Medicine, 5 Zaifu-cho, Hirosaki 036-8562, Japan.

OBJECTIVE Cyclosporin A (CsA) is utilized widely for treatment of inflammatory skin diseases, such as psoriasis vulgaris. The therapeutic effects of CsA are thought to be mediated by its immunosuppressive action on infiltrating lymphocytes in the lesional skin. CsA also inhibits epidermal keratinocyte proliferation, suggesting a direct biological action on keratinocytes. Here we tested the hypothesis that CsA can modulate the expression of the nuclear factor of activated T-cell (NFAT) in epidermal keratinocytes. We also investigated whether the keratinocyte-specific gene expression is modified by CsA through NFAT activity in association with differentiation induction. METHODS RT-PCR was performed using total RNAs extracted from cultured normal human epidermal keratinocytes (NHEK), normal human dermal fibroblasts (NHDF), and normal human epidermal melanocytes (NHEM) for detecting NFAT isomolecules. Transient transfections of NHEK with a 230-kDa bullous pemphigoid antigen (BPAG1) promoter/luciferase reporter gene and the luciferase assay were conducted for examining the effect of CsA on the promoter activity of the BPAG1 gene. Electrophoretic gel mobility shift assays (EMSA) with probes containing NFAT consensus sequences for analyzing the binding activities of the nuclear proteins extracted from NHEK. RESULTS RT-PCR revealed expression of all of the five isoforms of NFAT in the cell lines examined. The mRNA expression levels of NFAT1, NFAT2, BPAG1, and involucrin were downregulated by CsA treatment in NHEK. The luciferase assay indicated suppression of the promoter activity by CsA. EMSA with NFAT consensus probes identified in the BPAG1 promoter region demonstrated specific binding activity in the nuclear proteins of epidermal keratinocytes. CONCLUSIONS As reported previously, our results indicate that epidermal keratinocytes possess calcineurin/NFAT system, which is suppressed by CsA. In addition, the data suggest that CsA can downregulate the BPAG1 gene expression perhaps via the NFAT consensus cis-elements in the BPAG1 promoter region. Such transcriptional regulatory system might be involved in the regulation of keratinocyte differentiation and proliferation.

UI MeSH Term Description Entries
D008544 Melanocytes Mammalian pigment cells that produce MELANINS, pigments found mainly in the EPIDERMIS, but also in the eyes and the hair, by a process called melanogenesis. Coloration can be altered by the number of melanocytes or the amount of pigment produced and stored in the organelles called MELANOSOMES. The large non-mammalian melanin-containing cells are called MELANOPHORES. Melanocyte
D009419 Nerve Tissue Proteins Proteins, Nerve Tissue,Tissue Proteins, Nerve
D011401 Promoter Regions, Genetic DNA sequences which are recognized (directly or indirectly) and bound by a DNA-dependent RNA polymerase during the initiation of transcription. Highly conserved sequences within the promoter include the Pribnow box in bacteria and the TATA BOX in eukaryotes. rRNA Promoter,Early Promoters, Genetic,Late Promoters, Genetic,Middle Promoters, Genetic,Promoter Regions,Promoter, Genetic,Promotor Regions,Promotor, Genetic,Pseudopromoter, Genetic,Early Promoter, Genetic,Genetic Late Promoter,Genetic Middle Promoters,Genetic Promoter,Genetic Promoter Region,Genetic Promoter Regions,Genetic Promoters,Genetic Promotor,Genetic Promotors,Genetic Pseudopromoter,Genetic Pseudopromoters,Late Promoter, Genetic,Middle Promoter, Genetic,Promoter Region,Promoter Region, Genetic,Promoter, Genetic Early,Promoter, rRNA,Promoters, Genetic,Promoters, Genetic Middle,Promoters, rRNA,Promotor Region,Promotors, Genetic,Pseudopromoters, Genetic,Region, Genetic Promoter,Region, Promoter,Region, Promotor,Regions, Genetic Promoter,Regions, Promoter,Regions, Promotor,rRNA Promoters
D002352 Carrier Proteins Proteins that bind or transport specific substances in the blood, within the cell, or across cell membranes. Binding Proteins,Carrier Protein,Transport Protein,Transport Proteins,Binding Protein,Protein, Carrier,Proteins, Carrier
D002478 Cells, Cultured Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others. Cultured Cells,Cell, Cultured,Cultured Cell
D003598 Cytoskeletal Proteins Major constituent of the cytoskeleton found in the cytoplasm of eukaryotic cells. They form a flexible framework for the cell, provide attachment points for organelles and formed bodies, and make communication between parts of the cell possible. Proteins, Cytoskeletal
D003879 Dermatologic Agents Drugs used to treat or prevent skin disorders or for the routine care of skin. Agent, Dermatologic,Agent, Dermatological,Agents, Dermatologic,Dermatologic Agent,Dermatological Agents,Agents, Dermatological,Dermatological Agent
D005347 Fibroblasts Connective tissue cells which secrete an extracellular matrix rich in collagen and other macromolecules. Fibroblast
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000071821 Dystonin A plakin characterized by repeat sequences homologous to SPECTRIN and PLECTIN and C-terminal EF HAND MOTIFS. It functions as an integrator of INTERMEDIATE FILAMENTS, ACTIN and MICROTUBULES in cytoskeleton networks. It is required for anchoring intermediate filaments to the actin cytoskeleton in neural and muscle cells as well as anchoring KERATIN-containing intermediate filaments to HEMIDESMOSOMES in EPITHELIAL CELLS. 230 kDa Bullous Pemphigoid Antigen,230-240 kDa Bullous Pemphigoid Antigen,Bullous Pemphigoid Antigen 1,Hemidesmosomal Plaque Protein,230 240 kDa Bullous Pemphigoid Antigen

Related Publications

Takayuki Aizu, and Katsuto Tamai, and Hajime Nakano, and Daiki Rokunohe, and Yuka Toyomaki, and Jouni Uitto, and Daisuke Sawamura
April 2006, Experimental dermatology,
Takayuki Aizu, and Katsuto Tamai, and Hajime Nakano, and Daiki Rokunohe, and Yuka Toyomaki, and Jouni Uitto, and Daisuke Sawamura
December 2004, Experimental dermatology,
Takayuki Aizu, and Katsuto Tamai, and Hajime Nakano, and Daiki Rokunohe, and Yuka Toyomaki, and Jouni Uitto, and Daisuke Sawamura
March 1995, The Journal of biological chemistry,
Takayuki Aizu, and Katsuto Tamai, and Hajime Nakano, and Daiki Rokunohe, and Yuka Toyomaki, and Jouni Uitto, and Daisuke Sawamura
October 1999, The Journal of investigative dermatology,
Takayuki Aizu, and Katsuto Tamai, and Hajime Nakano, and Daiki Rokunohe, and Yuka Toyomaki, and Jouni Uitto, and Daisuke Sawamura
January 1995, The Journal of biological chemistry,
Takayuki Aizu, and Katsuto Tamai, and Hajime Nakano, and Daiki Rokunohe, and Yuka Toyomaki, and Jouni Uitto, and Daisuke Sawamura
January 1994, Dermatology (Basel, Switzerland),
Takayuki Aizu, and Katsuto Tamai, and Hajime Nakano, and Daiki Rokunohe, and Yuka Toyomaki, and Jouni Uitto, and Daisuke Sawamura
March 1995, The Journal of dermatology,
Takayuki Aizu, and Katsuto Tamai, and Hajime Nakano, and Daiki Rokunohe, and Yuka Toyomaki, and Jouni Uitto, and Daisuke Sawamura
January 1991, Cytogenetics and cell genetics,
Takayuki Aizu, and Katsuto Tamai, and Hajime Nakano, and Daiki Rokunohe, and Yuka Toyomaki, and Jouni Uitto, and Daisuke Sawamura
March 1996, The British journal of dermatology,
Takayuki Aizu, and Katsuto Tamai, and Hajime Nakano, and Daiki Rokunohe, and Yuka Toyomaki, and Jouni Uitto, and Daisuke Sawamura
August 1993, The Journal of clinical investigation,
Copied contents to your clipboard!